Nutriband Inc. (NASDAQ:NTRB – Get Free Report)’s stock price dropped 1.9% during trading on Friday. The stock traded as low as $4.84 and last traded at $4.9050. 7,026 shares were traded during mid-day trading, a decline of 67% from the average session volume of 21,149 shares. The stock had previously closed at $5.00.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on the stock. Wall Street Zen raised shares of Nutriband to a “hold” rating in a research report on Saturday, October 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Nutriband in a research note on Monday, September 28th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Nutriband currently has a consensus rating of “Sell”.
Check Out Our Latest Analysis on NTRB
Nutriband Stock Down 1.9%
The business has a 50-day moving average price of $6.51 and a 200-day moving average price of $4.46. The firm has a market capitalization of $59.63 million, a price-to-earnings ratio of -9.25 and a beta of 2.17.
Nutriband (NASDAQ:NTRB – Get Free Report) last issued its quarterly earnings results on Friday, September 4th. The company reported ($0.07) EPS for the quarter. The firm had revenue of $0.44 million for the quarter. Nutriband had a negative return on equity of 109.07% and a negative net margin of 430.35%.
Institutional Trading of Nutriband
An institutional investor recently bought a new position in Nutriband stock. Cetera Investment Advisers purchased a new stake in shares of Nutriband Inc. (NASDAQ:NTRB – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 15,989 shares of the company’s stock, valued at approximately $120,000. Cetera Investment Advisers owned 0.13% of Nutriband as of its most recent filing with the SEC. 19.70% of the stock is owned by institutional investors and hedge funds.
About Nutriband
Nutriband is a pharmaceutical company focused on developing transdermal products, which deliver medicines through the skin. The company also pursues related medical-device and consumer-product opportunities. Its core platform, AVERSA, is designed to make certain medicated patches harder to misuse or abuse. Nutriband is developing AVERSA-based products for drugs with abuse potential, including a fentanyl patch; these products are under development and should not be confused with approved treatments.
Further Reading
- Five stocks we like better than Nutriband
- Zscaler Got a Boost From Palo Alto, But Now It Has to Deliver.
- Bargain Hunting: Why Off-Price Retail Is Winning
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.
